Abstract
The risk of alcohol-induced liver disease (ALD) increases dose- and time-dependently with consumption of alcohol. The progression of the disease is well characterized; however, although the progression of alcohol-induced liver injury is well characterized, there is no universally-accepted therapy available to halt or reverse this process in humans. With better understanding of the mechanism(s) and risk factors that mediate the initiation and progression of this disease, rational targeted therapy can be developed to treat or prevent it in the clinics. Several models for experimental ALD exist, including non-human primates, micropigs and rodents. However, most researchers employ rodent models of ALD. Furthermore, the advent of genetically modified strains of rodents (e.g. ‘knockout’ mice) has increased the specificity of the hypotheses that can be directly tested. Based on these models systems, several plausible hypotheses to explain the mechanism(s) by which alcohol leads to liver damage have been proposed, including consequences of alcohol metabolism, oxidative/nitrosative stress, altered inflammatory responses, and increased sensitivity to cytotoxic stimuli. These studies have also identified candidate genes for polymorphism studies to explain potential increased genetic risk in some individuals. However, despite significant advances in our understanding of the mechanisms by which ALD develops based on studies with these models, this work has yet to translate to a viable therapy for ALD in the clinics. This talk will also discuss potential reasons for these limitations to date and suggest future prospects to improve the translational utility of modeling ALD.
References
1.
Lelbach WK: Liver damage in chronic alcoholism: results of a clinical, clinical-chemical and bioptic-histological study in 526 alcoholic patients during a low calorie diet in an open drinking sanatorium. Acta Hepatosplenol 1966;13:321–349.
2.
Diehl AM: Liver disease in alcohol abusers: clinical perspective. Alcohol 2002;27:7–11.
3.
Tsukamoto H, Reiderberger RD, French SW, Largman C: Long-term cannulation model for blood sampling and intragastric infusion in the rat. Am J Physiol 1984;247:R595–R599.
4.
Batra SC, Haber PS, Mirmiran-Yazdy AA, Korsten MA, Gentry RT, Lieber CS: Gastric metabolism of ethanol in Syrian golden hamster. Dig Dis Sci 1995;40:2712–2716.
5.
Lieber CS, Leo MA, Mak KM, DeCarli LM, Sato S: Choline fails to prevent liver fibrosis in ethanol-fed baboons but causes toxicity. Hepatology 1985;5:561–572.
6.
Lieber CS, Baraona E, Hernandez-Munoz R, Kubota S, Sato N, Kawano S, Matsumura T, Inatomi N: Impaired oxygen utilization: a new mechanism for the hepatotoxicity of ethanol in sub-human primates. J Clin Invest 1989;83:1682–1690.
7.
DeNoble VJ, Mele PC, Porter JH: Intravenous self-administration of pentobarbital and ethanol in rats. Pharmacol Biochem Behav 1985;23:759–763.
8.
Zhang P, Bagby GJ, Xie M, Stoltz DA, Summer WR, Nelson S: Acute ethanol intoxication inhibits neutrophil β2-integrin expression in rats during endotoxemia. Alcohol Clin Exp Res 1998;22:135–141.
9.
Slawecki CJ, Somes C, Ehlers CL: Effects of prolonged ethanol exposure on neurophysiological measures during an associative learning paradigm. Drug Alcohol Depend 2000;58:125–132.
10.
Thurman RG, Bradford BU, Iimuro Y, Knecht KT, Connor HD, Adachi Y, Wall CA, Arteel GE, Raleigh JA, Forman DT, Mason RP: Role of Kupffer cells, endotoxin and free radicals in hepatotoxicity due to prolonged alcohol consumption: gender studies in rats. J Nutr 1997;127:903S–906S.
11.
Thurman RG, Bradford BU, Iimuro Y, Knecht KT, Arteel GE, Yin M, Connor HD, Wall C, Raleigh JA, Frankenberg MV, Adachi Y, Forman DT, Brenner D, Kadiiska M, Mason RP: The role of gut-derived bacterial toxins and free radicals in alcohol-induced liver injury. J Gastroenterol Hepatol 1998;13(suppl):S39–S50.
12.
Arteel GE, Iimuro Y, Yin M, Raleigh JA, Thurman RG: Chronic enteral ethanol treatment causes hypoxia in rat liver tissue in vivo. Hepatology 1997;25:920–926.
13.
Enomoto N, Ikejima K, Yamashina S, Enomoto A, Nishiura T, Nishimura T, Brenner DA, Schemmer P, Bradford BU, Rivera CA, Zhong Z, Thurman RG: Kupffer cell-derived prostaglandin E2 is involved in alcohol-induced fat accumulation in rat liver. Am J Physiol Gastrointest Liver Physiol 2000;279:G100–G106.
14.
Adachi Y, Bradford BU, Gao W, Bojes HK, Thurman RG: Inactivation of Kupffer cells prevents early alcohol-induced liver injury. Hepatology 1994;20:453–460.
15.
Adachi Y, Moore LE, Bradford BU, Gao W, Thurman RG: Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995;108:218–224.
16.
Iimuro Y, Ikejima K, Rose ML, Bradford BU, Thurman RG: Nimodipine, a dihydropyridine-type calcium channel blocker, prevents alcoholic hepatitis due to chronic intragastric ethanol exposure in the rat. Hepatology 1996;24:391–397.
17.
Wheeler MD, Kono H, Yin M, Nakagami M, Uesugi T, Arteel GE, Gabele E, Rusyn I, Yamashina S, Froh M, Adachi Y, Iimuro Y, Bradford BU, Smutney OM, Connor HD, Mason RP, Goyert SM, Peters JM, Gonzalez FJ, Samulski RJ, Thurman RG: The role of Kupffer cell oxidant production in early ethanol-induced liver disease. Free Radic Biol Med 2001;31:1544–1549.
18.
Arteel GE, Raleigh JA, Bradford BU, Thurman RG: Acute alcohol produces hypoxia directly in rat liver tissue in vivo: role of Kupffer cells. Am J Physiol 1996;271:G494–G500.
19.
Yuki T, Thurman RG: The swift increase in alcohol metabolism: time course for the increase in hepatic oxygen uptake and the involvement of glycolysis. Biochem J 1980;186:119–126.
20.
Enomoto N, Ikejima K, Bradford BU, Rivera CA, Kono H, Brenner DA, Thurman RG: Alcohol causes both tolerance and sensitization of rat Kupffer cells via mechanisms dependent on endotoxin. Gastroenterology 1998;115:443–451.
21.
Colell A, Garcia-Ruiz C, Miranda M, Ardite E, Mari M, Morales A, Corrales F, Kaplowitz N, Fernandez-Checa JC: Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor. Gastroenterology 1998;115:1541–1551.
22.
Best CH, Hartroft WS, Lucas CC, Ridout JH: Liver damage produced by feeding alcohol or sugar and its prevention by choline. Br Med J 1949;ii:1001–1006.
23.
Rodd-Henricks ZA, Bell RL, Kuc KA, Murphy JM, McBride WJ, Lumeng L, Li TK: Effects of ethanol exposure on subsequent acquisition and extinction of ethanol self-administration and expression of alcohol-seeking behavior in adult alcohol-preferring rats. II. Adult exposure. Alcohol Clin Exp Res 2002;26:1642–1652.
24.
Smith DG, Learn JE, McBride WJ, Lumeng L, Li TK, Murphy JM: Long-term effects of alcohol drinking on cerebral glucose utilization in alcohol-preferring rats. Pharmacol Biochem Behav 2001;69:543–553.
25.
Lieber CS, DeCarli LM: Liquid diet technique of ethanol administration: 1989 update. Alcohol Alcohol 1989;24:197–211.
26.
Lieber CS, Jones DP, DeCarli LM: Effects of prolonged ethanol intake: production of fatty liver despite adequate diets. J Clin Invest 1965;44:1009–1021.
27.
Lieber CS, Spritz N, DeCarli LM: Role of dietary, adipose, and endogenously synthesized fatty acids in the pathogenesis of the alcoholic fatty liver. J Clin Invest 1966;45:51–62.
28.
Wheeler MD, Kono H, Rusyn I, Arteel GE, McCarty D, Jude SR, Thurman RG: Chronic ethanol increases adeno-associated viral transgene expression in rat liver via oxidant and NF-ĸB-dependent mechanisms. Hepatology 2000;32:1050–1059.
29.
Yin M, Wheeler MD, Kono H, Bradford BU, Gallucci RM, Luster MI, Thurman RG: Essential role of tumor necrosis factor-α in alcohol-induced liver injury. Gastroenterology 1999;117:942–952.
30.
Kono H, Rusyn I, Yin M, Gabele E, Yamashina S, Dikalova A, Kadiiska MB, Connor HD, Mason RP, Segal BH, Bradford BU, Holland SM, Thurman RG: NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. J Clin Invest 2000;106:867–872.
31.
Li J, Nguyen V, French BA, Parlow AF, Su GL, Fu P, Yuan QX, French SW: Mechanism of the alcohol cyclic pattern: role of the hypothalamic-pituitary-thyroid axis. Am J Physiol Gastrointest Liver Physiol 2000;279:G118–G125.
32.
De la M Hall P, Lieber CS, DeCarli LM, French SW, Lindros KO, Jarvelainen H, Bode C, Parlesak A, Bode JC: Models of alcoholic liver disease in rodents: a critical evaluation. Alcohol Clin Exp Res 2001;25:254S–261S.
33.
Tsukamoto H, Horne W, Kamimura S, Niemela O, Parkkila S, Yla-Herttuala S, Brittenham GM: Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest 1995;96:620–630.
34.
French SW, Miyamoto K, Tsukamoto H: Ethanol-induced hepatic fibrosis in the rat: role of the amount of dietary fat. Alcohol Clin Exp Res 1986;10:13S–19S.
35.
Takahashi H, Wong K, Jui L, Nanji AA, Mendenhall CS, French SW: Effect of dietary fat on Ito cell activation by chronic ethanol intake: a long-term serial morphometric study on alcohol-fed and control rats. Alcohol Clin Exp Res 1991;15:1060–1066.
36.
Kono H, Nakagami M, Rusyn I, Connor HD, Stefanovic B, Brenner DA, Mason RP, Arteel GE, Thurman RG: Development of an animal model of chronic alcohol-induced pancreatitis in the rat. Am J Physiol Gastrointest Liver Physiol 2001;280:G1178–G1186.
37.
Pandol SJ, Periskic S, Gukovsky I, Zaninovic V, Jung Y, Zong Y, Solomon TE, Gukovskaya AS, Tsukamoto H: Ethanol diet increases the sensitivity of rats to pancreatitis induced by cholecystokinin octapeptide. Gastroenterology 1999;117:706–716.
38.
Fadda F, Rossetti ZL: Chronic ethanol consumption: from neuroadaptation to neurodegeneration. Prog Neurobiol 1998;56:385–431.
39.
Hammond KB, Rumack BH, Rodgerson DO: Blood ethanol. A report of unusually high levels in a living patient. JAMA 1973;226:63–64.
40.
Urso T, Gavaler JS, Van Thiel DH: Blood ethanol levels in sober alcohol users seen in an emergency room. Life Sci 1981;28:1053–1056.
41.
Goldman MS: To drink or not to drink: an experimental analysis of group drinking decisions by four alcoholics. Am J Psychiatry 1974;131:1123–1130.
42.
Arteel G, Marsano L, Mendez C, Bentley F, McClain CJ: Advances in alcoholic liver disease. Best Pract Res Clin Gastroenterol 2003;17:625–647.
43.
Wu J, Norton PA: Animal models of liver fibrosis. Scand J Gastroenterol 1996;31:1137–1143.
44.
Tsukamoto H, Matsuoka M, French SW: Experimental models of hepatic fibrosis: a review. Semin Liver Dis 1990;10:56–65.
45.
Jiang Z, You DY, Chen XC, Wu J: Monitoring of serum markers for fibrosis during CCl4-induced liver damage. Effects of anti-fibrotic agents. J Hepatol 1992;16:282–289.
46.
Muller A, Machnik F, Zimmermann T, Schubert H: Thioacetamide-induced cirrhosis-like liver lesions in rats – usefulness and reliability of this animal model. Exp Pathol 1988;34:229–236.
47.
Ide M, Yamate J, Machida Y, Nakanishi M, Kuwamura M, Kotani T, Sawamoto O: Emergence of different macrophage populations in hepatic fibrosis following thioacetamide-induced acute hepatocyte injury in rats. J Comp Pathol 2003;128:41–51.
48.
Kon K, Ikejima K, Hirose M, Yoshikawa M, Enomoto N, Kitamura T, Takei Y, Sato N: Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun 2002;291:55–61.
49.
Kim KY, Choi I, Kim SS: Progression of hepatic stellate cell activation is associated with the level of oxidative stress rather than cytokines during CCl4-induced fibrogenesis. Mol Cells 2000;10:289–300.
50.
Grizzi F, Franceschini B, Gagliano N, Moscheni C, Annoni G, Vergani C, Hermonat PL, Chiriva-Internati M, Dioguardi N: Mast cell density, hepatic stellate cell activation and TGF-β1 transcripts in the aging Sprague-Dawley rat during early acute liver injury. Toxicol Pathol 2003;31:173–178.
51.
Kitamura K, Nakamoto Y, Akiyama M, Fujii C, Kondo T, Kobayashi K, Kaneko S, Mukaida N: Pathogenic roles of tumor necrosis factor receptor p55-mediated signals in dimethylnitrosamine-induced murine liver fibrosis. Lab Invest 2002;82:571–583.
52.
Honda H, Ikejima K, Hirose M, Yoshikawa M, Lang T, Enomoto N, Kitamura T, Takei Y, Sato N: Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology 2002;36:12–21.
53.
Hironaka K, Sakaida I, Uchida K, Okita K: Correlation between stellate cell activation and serum fibrosis markers in choline-deficient L-amino acid-defined diet-induced rat liver fibrosis. Dig Dis Sci 2000;45:1935–1943.
54.
Denda A, Endoh T, Tang Q, Tsujiuchi T, Nakae D, Konishi Y: Prevention by inhibitors of arachidonic acid cascade of liver carcinogenesis, cirrhosis and oxidative DNA damage caused by a choline-deficient, L-amino acid-defined diet in rats. Mutat Res 1998;402:279–288.
55.
Broitman SA, Gottlieb LS, Zamcheck N: Influence of neomycin and ingested endotoxin in the pathogenesis of choline deficiency cirrhosis in the adult rat. J Exp Med 1964;119:633–647.
56.
Lu SC, Tsukamoto H, Mato JM: Role of abnormal methionine metabolism in alcoholic liver injury. Alcohol 2002;27:155–162.
57.
Diehl AM: Nonalcoholic steatohepatitis. Semin Liver Dis 1999;19:221–229.
58.
Arteel GE: Oxidants and antioxidants in alcohol-induced liver disease. Gastroenterology 2003;124:778–790.
59.
Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Dannenberg AJ: Dietary saturated fatty acids reverse inflammatory and fibrotic changes in rat liver despite continued ethanol administration. J Pharmacol Exp Ther 2001;299:638–644.
60.
Yamada Y, Kirillova I, Peschon JJ, Fausto N: Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci USA 1997;94:1441–1446.
61.
Bergheim I, Guo L, Davis MA, Lambert JC, Beier JI, Duveau I, Luyendyk JP, Roth RA, Arteel GE: Metformin prevents alcohol-induced liver injury in the mouse: critical role of plasminogen activator inhibitor-1. Gastroenterology 2006;130:2099–2112.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
